Debiopharm Group
www.debiopharm.com
Latest From Debiopharm Group
Deal Watch: Cancer Remains Hot Target At J.P. Morgan
Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.
Tech Transfer Roundup: Amicus Adds Gene Therapy Technology In UPenn Partnership
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B
ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Cancer
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Alias(es)
- Debio Group
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Switzerland
-
Switzerland
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Debiopharm Group
- Senior Management
-
Rolland-Yves Mauvernay, Co-Pres.
Thierry Mauvernay, Co-Pres. - Contact Info
-
Debiopharm Group
Phone: (41) 21 321 0111
Chemin Messidor 5-7
P.O. Box 5911 Lausanne, CH-1002
Switzerland
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice